Xenon Pharmaceuticals Inc (XENE) Stock Analysis

Xenon Pharmaceuticals Inc (XENE) is a publicly traded company in the HEALTHCARE sector. It trades at $52.30, carries a market capitalization of $5.29B. This page summarizes the public market data, fundamentals, and frequently asked questions for XENE, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Xenon Pharmaceuticals Inc currently has a Bullish sentiment score of 0.29.

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Burnaby, Canada, dedicated to pioneering innovative therapies for neurological disorders. With a diverse and promising pipeline of drug candidates, the company utilizes cutting-edge technologies to address genetic and rare conditions, significantly enhancing patient care and treatment options. Xenon's unwavering commitment to scientific rigor and patient-centric outcomes underscores its strategic positio...

GNG Research Analysis

GNG Research scores Xenon Pharmaceuticals Inc (XENE) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for XENE.

Frequently Asked Questions

Does XENE pay dividends?

Xenon Pharmaceuticals Inc (XENE) does not currently pay a regular dividend.

What is XENE's market cap?

Xenon Pharmaceuticals Inc (XENE) has a market capitalization of $5.29B with a current stock price of $52.30.